Noom Pricing History and Trajectory: What You've Actually Paid Over Time

How Noom's Price Has Changed Year by Year

Noom began selling its weight-loss coaching subscription at aggressively discounted rates to grow its user base quickly. Between 2016 and 2019, annual-plan pricing averaged $18, $44 per month depending on promotional timing. That translates to roughly $216, $528 per year for what was, at the time, an app with daily lessons and human coaches who responded via text.

By 2021, Noom had raised its standard monthly price to approximately $59/month without a long-term commitment, while continuing to offer annual plans at a steep discount (often $149, $199 for the full year during sale windows). The company's S-1 filing documents from its aborted 2021 SPAC deal placed its average revenue per user at roughly $170 annually at that time.

Price increases accelerated after 2022. As of mid-2024, the month-to-month rate sits at $70/month. The annual plan lists at $209 per year (about $17.42/month), but Noom routinely discounts that to $99, $149 through promotional codes, making the effective price highly variable depending on when a user signs up.

The GLP-1 Tier: "Noom Med"

In 2023, Noom launched "Noom Med," a clinical arm that pairs its behavioral coaching app with prescriber access and GLP-1 receptor agonist medications. This add-on starts at $149/month and can exceed $400/month when compounded semaglutide or brand-name GLP-1 drugs are included. The FDA has clarified its position on compounded semaglutide and similar compounded GLP-1 products, noting serious adverse event reports linked to dosing errors and formulation inconsistencies.

Annual Plan vs. Month-to-Month: The Real Cost Gap

The gap between Noom's advertised annual price and its month-to-month price has widened over time. In 2019, the ratio was roughly 2.5:1. By 2024, that ratio has grown to approximately 4:1, a structure that heavily penalizes users who cancel before completing a full year. The Federal Trade Commission's guidelines on negative option marketing require clear disclosure of auto-renewal terms, a requirement Noom has faced scrutiny over.

Is Noom Legit? A Clinical and Regulatory Assessment

Noom is a legitimate, operating company with real behavioral-change content. The question worth asking is whether its clinical outcomes justify its price trajectory.

The Clinical Evidence Base

Noom has published internal efficacy data. A 2016 retrospective study on 35,921 Noom users found that 77.9% of participants reported weight loss, with 22.4% losing more than 10% of body weight over an average of 265 days (Michaelides et al., 2016, JMIR mHealth). Those are self-selected users who remained engaged, not an intention-to-treat population, which means the figures likely overstate real-world outcomes.

A randomized controlled trial published in Obesity examined app-based behavioral interventions similar to Noom's CBT model. The ORBIT trial (N=400) found that a digital CBT weight-loss program produced 3.2 kg mean weight loss at 24 weeks versus 0.6 kg in the control arm (Forman et al., 2019). That is a modest but statistically significant difference (P<0.001).

For context, the STEP-1 trial (N=1,961) showed that semaglutide 2.4 mg produced 14.9% mean weight loss at 68 weeks versus 2.4% with placebo (Wilding et al., 2021, NEJM). App-based coaching alone does not approach that magnitude of effect.

What the Guidelines Say About Behavioral Interventions

The U.S. Preventive Services Task Force recommends offering or referring adults with a BMI ≥30 to intensive, multicomponent behavioral counseling interventions (USPSTF, 2018). "Intensive" in USPSTF language means at least 12 sessions in the first year. Noom's coach contact frequency varies by plan tier and has declined on lower-cost plans over time, a documented complaint in BBB filings.

The American Association of Clinical Endocrinology's 2023 obesity guidelines recommend pharmacotherapy alongside behavioral intervention for patients who do not achieve clinically meaningful weight loss (5% or more of body weight) after 3 to 6 months of lifestyle changes alone (AACE 2023 Obesity Guidelines). Noom's GLP-1 tier is structurally consistent with this recommendation, though pricing places it out of reach for many patients.

Noom's Regulatory Standing

Noom is not an FDA-regulated medical device for its core coaching app. The coaching service operates under a direct-to-consumer model outside direct FDA oversight. However, its prescribing arm (Noom Med) involves licensed prescribers and falls under standard telehealth prescribing regulations, which vary by state. The company is not listed in the FDA's MedWatch database as a device manufacturer, consistent with its software-as-wellness positioning.

LegitScript, which certifies online pharmacies and healthcare providers, does not currently carry Noom's prescribing operation in its certified provider list as of July 2024. Users filling GLP-1 prescriptions through Noom Med should verify that the pharmacy dispensing the medication holds a valid state pharmacy license.

Noom Complaints: Patterns in BBB and Consumer Reports

The Better Business Bureau has logged over 2,300 complaints against Noom in the past three years, earning the company a B+ rating. The majority of complaints fall into three categories.

Auto-Renewal and Billing Disputes

Auto-renewal complaints dominate the BBB filings. Users report being charged for annual plan renewals after attempting to cancel, with some describing difficulty reaching customer support before the billing date. The FTC's Negative Option Rule, updated in 2023, requires companies to make cancellation as easy as sign-up. Noom modified its cancellation interface in late 2023 following scrutiny, adding a direct in-app cancellation path, but complaints have continued.

Coach Availability Declining on Base Plans

A recurring complaint in both BBB filings and FDA MedWatch-adjacent consumer forums involves coach responsiveness. Users on promotional or heavily discounted annual plans report response times of 48 to 72 hours or longer from their assigned coach. This represents a material degradation from earlier marketing claims of daily coach interaction. The USPSTF's intensity threshold of 12 or more sessions per year is difficult to meet if coach contact is effectively asynchronous with multi-day gaps.

Efficacy Gaps Between Marketing and Outcomes

Consumer complaints frequently reference the gap between Noom's marketing language (which has historically used "clinically proven" or "psychologist-designed" claims) and individual outcomes. The FTC's guidance on health claims requires that "clinically proven" language be backed by well-controlled human clinical trials. Noom's primary efficacy publication is a retrospective observational study, not an RCT, a distinction that several state attorneys general have noted in correspondence with the company.

Noom's GLP-1 Strategy: Pricing and Clinical Positioning

Adding a GLP-1 medication tier is a reasonable clinical decision given the STEP-1 evidence base. The pricing, however, creates access barriers that deserve scrutiny.

What Noom Med Costs in Practice

Noom Med charges $149/month for the prescriber consultation and care coordination layer. Medication costs are separate. Compounded semaglutide, sourced through Noom's partner pharmacies, has been priced in the $199, $350/month range. Combined costs can therefore reach $350, $500/month or more, depending on dose and pharmacy.

For comparison, the manufacturer list price for branded Ozempic (semaglutide 0.5 to 2 mg for type 2 diabetes) is approximately $935/month without insurance (GoodRx market data, July 2024). Compounded versions are substantially cheaper but carry the formulation and dosing risks the FDA has flagged.

The FDA's Position on Compounded Semaglutide

The FDA added semaglutide to its drug shortage list in 2022, which temporarily permitted compounding under section 503A and 503B of the Federal Food, Drug, and Cosmetic Act. As of early 2024, the FDA announced that the shortage for semaglutide injection had been resolved, creating a pathway for enforcement against compounders who continue producing it outside shortage exemptions. Platforms like Noom Med that have been relying on compounded semaglutide may need to transition users to branded products or adjust their medication sourcing, which would substantially raise their pricing.

Clinical Outcomes with GLP-1 Plus Behavioral Support

The SURMOUNT-1 trial (N=2,539) demonstrated that tirzepatide (a GIP/GLP-1 dual agonist) at 15 mg produced a mean weight loss of 20.9% at 72 weeks, compared to 3.1% with placebo (Jastreboff et al., 2022, NEJM). All trial participants received a lifestyle intervention component, which approximates the combined behavioral-plus-medication model Noom Med offers.

The SELECT trial (N=17,604) showed cardiovascular risk reduction with semaglutide 2.4 mg (Wegovy), with a 20% relative risk reduction in major adverse cardiovascular events (Lincoff et al., 2023, NEJM). These benefits are attributable to the medication, not the behavioral coaching layer, though coaching may support medication adherence and lifestyle change that compounds the medication benefit.

Price-to-Value Analysis: Who Gets the Most Out of Noom

Not every user gets the same value from Noom at any price point. The platform's CBT-based curriculum has a defined evidence base for modest weight loss in motivated users. At $17.42/month on an annual plan (with a promotional code), that is a reasonable cost if it is used consistently.

Users Who May Benefit From the App Tier

Adults with a BMI of 25 to 30 who want structured behavioral support and accountability without pharmacotherapy represent Noom's best-fit user profile. The CDC's clinical practice guidelines for obesity management endorse behavioral interventions as first-line treatment for overweight adults without major comorbidities. For this group, a $99, $209 annual Noom subscription compares favorably to weekly in-person dietitian visits, which average $75, $125 per session out of pocket.

Users Who Likely Need More Than the App

Adults with a BMI ≥30 and comorbidities (type 2 diabetes, hypertension, obstructive sleep apnea) will typically not achieve clinically meaningful weight loss from behavioral coaching alone. The AACE 2023 guidelines explicitly state that pharmacotherapy should be offered concurrently with lifestyle intervention in this population, not sequentially. For these patients, the relevant question is whether Noom Med's total cost ($350, $500+/month) is competitive with other telehealth GLP-1 platforms.

Price Comparison With Competing Telehealth GLP-1 Platforms

Several telehealth competitors offer GLP-1 prescribing and coaching at comparable or lower all-in costs. Ro Body, Found, and WeightWatchers Clinic have each priced their combined coaching-plus-medication tiers in the $200, $400/month range, often with more transparent medication pricing than Noom Med has historically published. The competitive pressure in this market is likely to constrain Noom's ability to raise prices further without materially improving its clinical outcomes data.

What to Watch: Price Trajectory Through 2025

Three factors are likely to shape Noom's pricing in the next 12 months.

The first is FDA compounding enforcement. If the FDA restricts compounded semaglutide distribution, Noom Med's medication costs will rise sharply. The FDA's December 2023 alert on compounded GLP-1 products signaled increasing regulatory attention to this space.

The second is competitive pressure. WeightWatchers acquired the telehealth prescribing platform Sequence in 2023, directly challenging Noom Med. Increased competition historically suppresses price increases or forces them to be paired with added-value features.

The third is insurance coverage expansion. As more commercial insurers cover GLP-1 medications for obesity (following CMS's proposed rule to cover Wegovy for Medicare beneficiaries with cardiovascular disease), the out-of-pocket portion of GLP-1 costs may decrease, shifting price competition to the platform and coaching tier rather than medication access.

A peer-reviewed economic analysis in JAMA Internal Medicine found that semaglutide for obesity prevention would need to be priced at approximately $7,500 per year or less to meet standard cost-effectiveness thresholds (Shao et al., 2023). Noom Med's all-in annual cost already approaches or exceeds that threshold for some users, raising legitimate questions about value relative to clinical benefit.